We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01666613
First Posted: August 16, 2012
Last Update Posted: December 19, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
August 14, 2012
August 16, 2012
December 19, 2012
November 2012
March 2013   (Final data collection date for primary outcome measure)
Absolute pulmonary bioavailability of AZD8683 delivered by the new dry powder inhaler in terms of: Fpulmonary [ Time Frame: Blood samples taken pre-dose and at 5, 15 and 30 minutes and 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post dose. ]
Same as current
Complete list of historical versions of study NCT01666613 on ClinicalTrials.gov Archive Site
  • Absolute pulmonary bioavailability of AZD8683 delivered by the Turbuhaler™ in terms of: Fpulmonary [ Time Frame: Blood samples taken pre-dose and at 5, 15 and 30 minutes and 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post dose. ]
  • Pharmacokinetics of AZD8683 following administration in terms of oral inhalation by Turbuhaler™ and New Dry Powder Inhaler in terms of: Finhalation total, FrelAUC, Frel Cmax and Foral [ Time Frame: Blood samples taken pre-dose and at 5, 15 and 30 minutes and 1, 2, 4, 8, 12,24, 36, 48, 72, 96, 120 and 144 hours post dose. ]
  • Pharmacokinetics of AZD8683 following oral administration in terms of: Fpo [ Time Frame: Blood samples taken pre-dose and at 5, 15 and 30 minutes and 1, 2, 4, 8, 12 ,24, 36, and 48 hours post dose. ]
  • Pharmacokinetics of AZD8683 following oral administration and oral inhalation by Turbuhaler™ and New Dry Powder inhaler in terms of : AUC, AUC(0-t), Cmax, tmax, t½λz, MRT and MAT. [ Time Frame: Blood samples taken pre-dose and at 5, 15 and 30 minutes and 1, 2, 4, 8, 12,24, 36, 48, 72 96, 120 and 144 hours post dose. ]
  • Pharmacokinetics of AZD8683 following i.v. administration in terms of: CL, Vz, and Vss [ Time Frame: Blood samples taken pre-dose and at 5, 15, 20, 25 and 40 minutes and 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 144 hours post dose. ]
  • Safety profile in terms of adverse events, ECG, heart rate, blood pressure, body temperature, physical examination, spirometry, haematology, clinical chemistry and urinalysis. [ Time Frame: Screening to 4 weeks after last dose. ]
    No formal statistical tests will be performed.
Same as current
Not Provided
Not Provided
 
A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways
A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 When Administered Inhaled Via a New Dry Powder Inhaler and Via Turbuhaler™
The purpose of this study is to look at drug levels of AZD8683 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with two different devices), to healthy subjects
A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 when Administered Inhaled via a New Dry Powder Inhaler and via Turbuhaler™
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Healthy
  • Drug: AZD8683
    Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
  • Drug: AZD8683
    Solution to be administered orally Total dose of 950 µg AZD8683
  • Drug: AZD8683
    Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
  • Drug: AZD8683
    Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
  • Experimental: 1
    AZD8683 iv
    Intervention: Drug: AZD8683
  • Experimental: 2
    AZD8683 oral
    Intervention: Drug: AZD8683
  • Experimental: 3
    AZD8683 inhalation New Dry Powder Inhaler
    Intervention: Drug: AZD8683
  • Experimental: 4
    AZD8683 inhalation Turbuhaler™
    Intervention: Drug: AZD8683
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
March 2013
March 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy males or women of non-childbearing potential aged 18-45 years inclusive with suitable veins for cannulation or repeated vein puncture
  • Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive) and weight between 50 and 100 kg (inclusive)
  • Be able to inhale from the inhaler devices used in the study.

Exclusion Criteria:

  • History of any clinically significant disease or disorder
  • Current smokers
  • Any clinically relevant abnormal findings in physical examination or laboratory values.
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01666613
D1883C00008
EudraCT number 2012-002901-23
Not Provided
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Study Director: Carin Jorup, MD AstraZeneca R&D, Molndal Sweden
AstraZeneca
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP